The European treatment of severe atopic eczema in children taskforce (TREAT) survey

Abstract

In the absence of a clear evidence base, the European TREAT survey confirms the wide variation in prescribing practice of systemic immunosuppression in refractory paediatric atopic eczema. The results will be used to inform the design of a randomized controlled trial relevant to patient management across Europe.

Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: The PeDRA TREAT survey

“…2 In 2014, the Pediatric Dermatology Research Alliance (PeDRA) launched the TREAT US&CANADA survey in collaboration with the European TREAT team: (i) to produce data on the current systemic agent prescribing practices of pediatric dermatologists for severe AD in the United States and Canada; (ii) to investigate factors influencing the use of specific systemic agents; and (iii) to inform the design of future intervention studies.…”

Epidemiology and Comorbidity in Children with Psoriasis and Atopic Eczema

“…It is characterised by pathognomonic eczematous skin lesions, typically with a flexural distribution, and often affects children's faces. Atopic eczema is associated with psychosocial stress and a family history of allergies [13,14,15]. In general atopic eczema starts in early childhood and features clinical symptoms including pruritus and skin dryness.…”

The International TREatment of ATopic Eczema (TREAT) Registry Taskforce: An Initiative to Harmonize Data Collection across National Atopic Eczema Photo- and Systemic Therapy Registries

“…(Garritsen et al, 2015;van der Schaft et al, 2015)). Despite this, in the absence of approved alternatives, immunomodulatory treatments are frequently prescribed as off-label therapies in children and adults, as shown in our recent European and North American surveys (Proudfoot et al, 2013;Taylor et al, 2016;Totri et al, 2017). Inclusion criteria for clinical trials are stringent; research in psoriasis suggests that around 30% of patients on systemic therapies entered into registries (in itself a very selected subgroup of all patients on systemic therapy) would not be eligible for a clinical trial, underscoring the value of 'real world' patient data (Garcia-Doval et al, 2012).…”